Caring for an ill or disabled family member imposes a well-documented burden on the caregiver. The benefits of a health intervention may be underestimated if “spillover” effects on family members are not captured, resulting in inaccurate conclusions of economic evaluations.
For the context of this special issue, family spillover is defined as the effect on an individuals’ quality of life due to having a family member with a chronic illness. We consider spillover to include family caregivers as well as non-caregivers. Extensions to larger social networks may also be included with justification (e.g., classmates for children’s illnesses).
Topics of interest include:
Applications: Measurement of spillover for specific conditions or populations of interest, inclusion of spillover in cost-effectiveness analyses.
Methods: Conceptual frameworks, measurement tools or approaches, methodological or practical issues in measurement; challenges to application in CEA.
Please submit an abstract describing your proposed paper by July 31, 2017 to the Editor, Chris Carswell . Full papers will be invited by August 31, 2017 and manuscripts due in early 2018.
AdisInsightThe recent first global approval of sarilumab has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.
Representatives from our Adis BI team recently attended the Advances in Drug Discovery conference, which took place at The Wellcome Genome Campus Conference Centre in Cambridge on 6th and 7th March 2017.
The second in a two-part series of live webinars on Pharmacovigilance and Safety Biomarkers is set to take place on Tuesday, March 21, 2017.
Joining forces with Amplion, the leading biomarker business intelligence company, we aim to provide useful insights for anyone involved in R&D, product strategy decisions, or working directly in a drug safety related role.